Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 13/20 | 0.47 |
| ▸ | GPR183 | P32249 | 5/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 10/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 10/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4280335 | 0.87 | ITGAL (0.44) | ITGALGPR183ITGB2ICAM1ENPP2 | |
| SCHEMBL4280329 | 0.87 | ITGAL (0.44) | ITGALGPR183ITGB2ICAM1ENPP2 | |
| SCHEMBL13879682 | 0.83 | ITGAL (0.56) | ITGALGPR183ITGB2ICAM1 | |
| SCHEMBL13879669 | 0.83 | ITGAL (0.54) | ITGALITGB2ICAM1 | |
| SCHEMBL13879673 | 0.82 | ITGAL (0.54) | ITGALGPR183ITGB2ICAM1 | |
| SCHEMBL4290339 | 0.78 | ITGAL (0.71) | ITGALITGB2ICAM1ENPP2 | |
| SCHEMBL4290345 | 0.78 | ITGAL (0.71) | ITGALITGB2ICAM1ENPP2 | |
| SCHEMBL4280109 | 0.78 | ITGAL (0.43) | ITGALGPR183ITGB2ICAM1ENPP2 | |
| SCHEMBL4280115 | 0.78 | ITGAL (0.43) | ITGALGPR183ITGB2ICAM1ENPP2 | |
| SCHEMBL13879676 | 0.75 | ITGAL (0.65) | ITGALITGB2ICAM1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | ITGAL 4495/4885GPR183 1510/4885ITGB2 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.